U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H22N2S.BrH
Molecular Weight 379.358
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VORTIOXETINE HYDROBROMIDE

SMILES

Br.CC1=CC(C)=C(SC2=CC=CC=C2N3CCNCC3)C=C1

InChI

InChIKey=VNGRUFUIHGGOOM-UHFFFAOYSA-N
InChI=1S/C18H22N2S.BrH/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20;/h3-8,13,19H,9-12H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H22N2S
Molecular Weight 298.446
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Vortioxetine is an antidepressant for the treatment of major depressive disorder. Vortioxetine’s mechanism of action is not fully understood. Vortioxetine binds with high affinity to the serotonin transporter and its antidepressant actions are believed to be secondary to enhancing serotonin in the central nervous system through inhibition of reuptake. Vortioxetine also displays binding affinities to other serotonin (5-HT) receptors, including 5-HT3, 5-HT1A, and 5-HT7. Due to multimodal neurotransmitter enhancer profile, it has been suggested that it might need lesser receptor occupancy rate for clinical trials than other selective serotonin reuptake inhibitors and selective norepinephrine reuptake inhibitors. Since vortioxetine is an agonist and antagonist of multiple serotonin receptors, potential interactions may occur with other medications that alter the serotonergic pathways. There is an increased risk of serotonin syndrome when vortioxetine is used in combination with other serotonergic agents.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
3.7 nM [Ki]
19.0 nM [Ki]
54.0 nM [Ki]
33.0 nM [Ki]
15.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BRINTELLIX

Cmax

ValueDoseCo-administeredAnalytePopulation
17.92 ng/mL
10 mg 1 times / day multiple, oral
VORTIOXETINE plasma
Homo sapiens
4.6 ng/mL
10 mg single, oral
VORTIOXETINE plasma
Homo sapiens
33 ng/mL
20 mg 1 times / day steady-state, oral
VORTIOXETINE plasma
Homo sapiens
1.374 ng/mL
5 mg single, oral
LU-AA34443 plasma
Homo sapiens
2.654 ng/mL
5 mg single, oral
LU-AA34443 plasma
Homo sapiens
0.008 ng/mL
5 mg single, oral
LU-AA39835 plasma
Homo sapiens
0.0289999999999999 ng/mL
5 mg single, oral
LU-AA39835 plasma
Homo sapiens
1.67 ng/mL
5 mg single, oral
VORTIOXETINE plasma
Homo sapiens
2.078 ng/mL
5 mg single, oral
VORTIOXETINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
344 ng × h/mL
10 mg 1 times / day multiple, oral
VORTIOXETINE plasma
Homo sapiens
273.42 ng × h/mL
10 mg single, oral
VORTIOXETINE plasma
Homo sapiens
71.942 ng*h/mL
5 mg single, oral
LU-AA34443 plasma
Homo sapiens
88.614 ng*h/mL
5 mg single, oral
LU-AA34443 plasma
Homo sapiens
122.899 ng*h/mL
5 mg single, oral
LU-AA34443 plasma
Homo sapiens
124.708 ng*h/mL
5 mg single, oral
LU-AA34443 plasma
Homo sapiens
0.078 ng*h/mL
5 mg single, oral
LU-AA39835 plasma
Homo sapiens
1.143 ng*h/mL
5 mg single, oral
LU-AA39835 plasma
Homo sapiens
166.955 ng*h/mL
5 mg single, oral
VORTIOXETINE plasma
Homo sapiens
188.662999999999 ng*h/mL
5 mg single, oral
VORTIOXETINE plasma
Homo sapiens
187.202 ng*h/mL
5 mg single, oral
VORTIOXETINE plasma
Homo sapiens
288.053 ng*h/mL
5 mg single, oral
VORTIOXETINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
58.84 h
10 mg 1 times / day multiple, oral
VORTIOXETINE plasma
Homo sapiens
60.62 h
10 mg single, oral
VORTIOXETINE plasma
Homo sapiens
66 h
20 mg 1 times / day steady-state, oral
VORTIOXETINE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
10 mg 1 times / day multiple, oral
VORTIOXETINE plasma
Homo sapiens
1%
10 mg single, oral
VORTIOXETINE plasma
Homo sapiens
2%
20 mg 1 times / day steady-state, oral
VORTIOXETINE plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended starting dose is 10 mg administered orally once daily without regard to meals. The dose should then be increased to 20 mg/day, as tolerated. Consider 5 mg/day for patients who do not tolerate higher doses. TRINTELLIX can be discontinued abruptly. However, it is recommended that doses of 15 mg/day or 20 mg/day be reduced to 10 mg/day for one week prior to full discontinuation if possible. The maximum recommended dose is 10 mg/day in known CYP2D6 poor metabolizers.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
TKS641KOAY
Record Status Validated (UNII)
Record Version